Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2011

01-05-2011 | Epidemiology

Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤40 years

Authors: Maurice J. C. van der Sangen, Fenneke M. M. van de Wiel, Philip M. P. Poortmans, Vivianne C. G. Tjan-Heijnen, Grard A. P. Nieuwenhuijzen, Rudi M. H. Roumen, Miranda F. Ernst, M. Cathelijne B. J. E. Tutein Nolthenius-Puylaert, Adri C. Voogd

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Login to get access

Abstract

To compare the effectiveness of breast-conserving therapy (BCT) and mastectomy, all women aged ≤40 years, treated for early-stage breast cancer in the southern part of the Netherlands between 1988 and 2005, were identified. A total of 562 patients underwent mastectomy and 889 patients received BCT. During follow-up, 23 patients treated with mastectomy and 135 patients treated with BCT developed a local relapse without previous or simultaneous evidence of distant disease. The local relapse risk for patients treated with mastectomy was 4.4% (95% confidence interval (CI) 2.4–6.4) at 5 years and reached a plateau after 6 years at 6.0% (95% CI 3.5–8.5). After BCT, the 5-, 10- and 15-year risks were 8.3% (95% CI 6.3–10.5), 18.4% (95% CI 15.0–21.8) and 28.2% (95% CI 23.0–33.4), respectively (P < 0.0001). Adjuvant systemic therapy following BCT reduced the 15-year local relapse risk from 32.9% (95% CI 26.7–39.1) to 16.1% (95% CI 9.1–23.1), (P = 0.0007). In conclusion, local tumor control in young patients with early-stage breast cancer is worse after BCT than after mastectomy. Adjuvant systemic therapy significantly improves local control following BCT and also for that reason it should be considered for most patients ≤40 years. Long-term follow-up is highly recommended for young patients after BCT, because even with systemic treatment an annual risk of local relapse of 1% remains up to 15 years after treatment.
Literature
1.
Veronesi U, Cascinelli N, Mariani L, Grecco M, Saccozzi R, Luini A, Aguilar M, Marubini E (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(16):1227–1232PubMedCrossRef
2.
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong J-H, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16)
3.
Van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, Van der Schueren E, Helle PA, Van Zijl K, Bartelink H (2000) Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European organization for research and treatment of cancer 10801 trial. J Natl Cancer Inst 92(14):1143–1150PubMedCrossRef
4.
Jacobson JA, Danforh DN, Cowan KH, D’Angelo T, Steinberg SM, Pierce L, Lippman ME, Lichter AS, Glatstein E, Okunieff P (1995) Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 332(14):907–911PubMedCrossRef
5.
Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, Mouridsen HT (1992) Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish breast cancer cooperative group. J Natl Cancer Inst Monogr (11):19–25
6.
Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, Van Tienhoven G, West Andersen K, Sylvester RJ, Van Dongen JA (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results for two large European randomized trials. J Clin Oncol 19(6):1688–1697PubMed
7.
De Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, Van de Velde CJ (2006) Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European organisation for research and treatment of cancer studies. Eur J Cancer 42(3):351–356PubMedCrossRef
8.
Vrieling C, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Bing Oei S, Peterse HL, Pierart M, Poortmans PM, Struikmans H, Van den Bogaert W, Bartelink H (2003) Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer 39(7):932–944PubMedCrossRef
9.
Elkhuizen PHM, Van de Vijver MJ, Hermans J, Zonderland HM, Van de Velde CJ, Leer J-WH (1998) Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 40(4):859–867PubMedCrossRef
10.
Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F, Poortmans PM, Oei SB, Collette L, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Schinagl DA, Wárlám-Rodenhuis CC, Bartelink H (2009) Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 27(30):4939–4947PubMedCrossRef
11.
Jobsen JJ, Van der Palen J, Ong F, Meerwaldt JH (2003) The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int J Radiat Oncol Biol Phys 57(3):724–731PubMedCrossRef
12.
Arriagada R, Lê MG, Guinebretière J-M, Dunant A, Rochard F, Tursz T (2003) Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients. Ann Oncol 14(11):1617–1622PubMedCrossRef
13.
Van der Leest M, Evers L, Van der Sangen MJC, Poortmans PM, Van de Poll-Franse LV, Vulto AJ, Nieuwenhuijzen GAP, Brenninkmeijer SJ, Creemers G, Voogd AC (2007) The safety of breast-conserving therapy in patients with breast cancer aged ≤40 years. Cancer 109(10):1957–1964PubMedCrossRef
14.
Lammers EJR, Huibers P, Van der Sangen MJC, Van de Poll-Franse LV, Poortmans PM, Ernst MF, Lemaire BMD, Meijs CMEM, Nuytinck HKS, Voogd AC (2010) Factors contributing to improved local control after mastectomy in patients with breast cancer aged 40 years or younger. Breast 19(1):44–49PubMedCrossRef
15.
Coulombe G, Tyldesley S, Speers C, Paltiel C, Aquino-Parsons C, Bernstein V, Truong P, Keyes M, Olivotto IA (2007) Is mastectomy superior to breast-conserving treatment for young women? Int J Radiat Oncol Biol Phys 67(5):1282–1290PubMedCrossRef
16.
Beadle BM, Woodward WA, Tucker SL, Outlaw ED, Allen PK, Oh JL, Strom EA, Perkins GH, Tereffe W, Yu T, Meric-Bernstam F, Litton JK, Buchholz TA (2009) Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys 73(3):734–744PubMedCrossRef
17.
Kroman N, Holtveg H, Wohlfart J, Jensen M-B, Mouridsen HT, Blichert-Toft M, Melbye M (2004) Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 100(4):688–693PubMedCrossRef
18.
Bontenbal M, Nortier JW, Beex LV, Bakker P, Hupperets PS, Nooij MA, Van Veelen H, Vreugdenhil G, Richel DJ, Bijham GH (2000) Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology. Ned Tijdschr Geneeskd 144(21):984–989PubMed
19.
Goldhirsch A, Glick JH, Gelber RD, Senn HJ (1998) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 90(21):1601–1608PubMedCrossRef
20.
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 19(18):3817–3827PubMed
21.
Zhou P, Gautam S, Recht A (2007) Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 101(1):51–57PubMedCrossRef
22.
Kreike B, Hart AMA, Van de Velde T, Borger J, Peterse H, Rutgers E, Bartelink H, Van de Vijver MJ (2008) Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. Int J Radiat Oncol Biol Phys 71(4):1014–1021PubMedCrossRef
23.
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y (2005) Effects of radiotherapy and differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106PubMed
24.
Punglia RS, Morrow M, Winer EP, Harris JR (2007) Local therapy and survival in breast cancer. N Engl J Med 356(23):2399–2405PubMedCrossRef
25.
Voogd AC, Repelaer van Driel OJ, Roumen RMH, Crommelin MA, Van Beek MWPM, Coebergh JWW (1997) Changing attitudes towards breast-conserving treatment of early breast cancer in the south-eastern Netherlands: results of a survey among surgeons and a registry-based analysis of patterns of care. Eur J Surg Oncol 23(2):134–138PubMedCrossRef
26.
Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, Hortobagyi GN, Cristofanilli M, Esteva FJ, Newman L, Singletary ES, Buzdar AU, Hunt KK (2001) Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol 19(8):2240–2246PubMed
27.
Kroman N, Jensen M-B, Wohlfart J, Mouridsen HT, Andersen PK, Melbye M (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320(7233):474–478PubMedCrossRef
28.
Park CC, Mitsumori M, Nixon A, Recht A, Connoly J, Gelman R, Silver B, Hetelekidis S, Abner A, Harris JR, Schnitt SJ (2000) Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: Influence of margin status and systemic therapy on local recurrence. J Clin Oncol 18(8):1668–1675PubMed
29.
McGrath S, Antonucci J, Goldstein N, Wallace M, Mitchell C, Grills I, Jolly S, Kestin L, Vicini F (2010) Long-term patterns of in-breast failure in patients with early stage breast cancer treated with breast-conserving therapy: a molecular based clonality evaluation. Am J Clin Oncol 33(1):17–22PubMedCrossRef
30.
Schlechter BL, Yang Q, Larson PS, Golubeva A, Blanchard RA, de las Morenas A, Rosenberg CL (2004) Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol 22(10):1830–1838PubMedCrossRef
31.
Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shares patterns of gene expression. J Clin Oncol 26(20):3324–3330PubMedCrossRef
32.
Kreike B, Halfwerk H, Armstrong N, Bult P, Foekens JA, Veltkamp SC, Nuyten DSA, Bartelink H, Van de Vijver MJ (2009) Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 15(12):4181–4190PubMedCrossRef
33.
Ellsworth DL, Ellsworth RE, Love B, Deyarmin B, Lubert SM, Mittal V, Shriver CD (2004) Genomic patterns of allelic imbalance in disease free tissue adjacent to primary breast carcinomas. Breast Cancer Res Treat 88(2):131–139PubMedCrossRef
34.
Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang THM (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12(22):6626–6636PubMedCrossRef
35.
De Sanjosé S, Léoné M, Bérez V, Izquierdo A, Font R, Brunet JM, Louat T, Vilardell L, Borras J, Viladiu P, Bosch FX, Lenoir GM, Sinilnikova OM (2003) Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population based study. Int J Cancer 106(4):588–593PubMedCrossRef
36.
Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24(16):2437–2443PubMedCrossRef
37.
Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359(9316):1471–1477PubMedCrossRef
38.
Alpert TE, Haffty BG (2004) Conservative management of breast cancer in BRCA1/2 mutation carriers. Clin Breast Cancer 5(1):37–42PubMedCrossRef
39.
Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Melgaard Nielsen H, Overgaard M (2008) Estrogen receptor, progesterone receptor, HER-2, and response to mastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 26(9):1419–1426PubMedCrossRef
40.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684PubMedCrossRef
Metadata
Title
Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤40 years
Authors
Maurice J. C. van der Sangen
Fenneke M. M. van de Wiel
Philip M. P. Poortmans
Vivianne C. G. Tjan-Heijnen
Grard A. P. Nieuwenhuijzen
Rudi M. H. Roumen
Miranda F. Ernst
M. Cathelijne B. J. E. Tutein Nolthenius-Puylaert
Adri C. Voogd
Publication date
01-05-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1110-x

Other articles of this Issue 1/2011

Breast Cancer Research and Treatment 1/2011 Go to the issue

Brief Report

Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis

Preclinical study

Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin

Invited Commentary

Dead-box or black-box: is DDX1 a potential biomarker in breast cancer?

Preclinical study

Identification of immunodominant HLA-B7-restricted CD8+ cytotoxic T cell epitopes derived from mammaglobin-A expressed on human breast cancers

Clinical trial

Randomized, double-blind comparison of indocyanine green with or without albumin premixing for near-infrared fluorescence imaging of sentinel lymph nodes in breast cancer patients

Clinical trial

The effect of various vitamin D supplementation regimens in breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits